To facilitate future research on the medication and its contaminants, this study collects the essential data required to develop analytical methods for assessing linagliptin. Because it increases insulin secretion and controls blood sugar levels, linagliptin (DPPIV inhibitor). The need for novel analytical methods is growing along with the quantity of newly manufactured pharmaceuticals, especially for those that are not yet listed in pharmacopoeias. The many analytical techniques for linagliptin, including HPLC, LC-MS, LC-PDA, UPLC, HPTLC, HILIC-UV, and UV spectrophotometry, are covered in this review.
Linagliptin is mostly measured using (RP-HPLC), either alone or in concoction with other drugs i.e., metformin or empagliflozin. A common RP-HPLC method for determining linagliptin uses a column: C18 (250 x 4.6 mm, 5μ), a mobile phase: 0.3% triethylamine & methanol (60:40 v/v) at a flow rate of 1 ml/min, & monitoring at 292 nm. This study highlights that more analytical advancements are required to examine the impurity profile of linagliptin, particularly 4-(Methylquinazoline-2-yl) methanol, which has not been examined in previous studies. When these methods are combined, this review provides a useful tool for researchers looking to improve Linagliptin analysis techniques, ensuring the effectiveness, security, and caliber of pharmaceutical items that contain this drug.